Diabetic macular edema (DME)
- Intravitreal anti-VEGF is first-line for center-involving vision loss
- Aflibercept/bevacizumab/ranibizumab/faricimab options
- Steroid implant for selected refractory/pseudophakic cases
- Laser retains selected noncentral roles
- Optimize glycemia/BP/kidney disease
- OCT guides response and retreatment
Use at a glance
- Intravitreal anti-VEGF is first-line for center-involving vision loss
Practical pearls
- Aflibercept/bevacizumab/ranibizumab/faricimab options
Monitoring / follow-up
- Optimize glycemia/BP/kidney disease
- OCT guides response and retreatment
Escalation / refractory disease
- Steroid implant for selected refractory/pseudophakic cases
- Laser retains selected noncentral roles
Self-check
- What should be optimized in Diabetic macular edema (DME)?
glycemia/BP/kidney disease.
- What is first-line treatment for Diabetic macular edema (DME)?
Intravitreal anti-VEGF.
Drugs used for this (4)
All clinical uses · Open the interactive console ↗
